Rucaparib治疗复发性铂敏感高级别卵巢癌(ARIEL2第1部分):一项国际、多中心、开放标签、2期试验
ARIEL2第1部分是一项国际、多中心、开放标签2期研究,于2013年10月30日至2014年12月19日入组206例复发性铂敏感高级别卵巢癌患者,按肿瘤突变分析分为BRCA突变、LOH高和LOH低三组,口服Rucaparib 600 mg每日两次。主要终点无进展生存期在BRCA突变组为12.8个月(95%CI 9.0-14.7),LOH高组为5.7个月(5.3-7.6),LOH低组为5.2个月(3.6-5.5);BRCA突变组和LOH高组较LOH低组的风险比分别为0.27(95%CI 0.16-0.44,p<0.0001)和0.62(95%CI 0.42-0.90,p=0.011)。
要点
- BRCA突变组中位无进展生存期12.8个月,LOH高组5.7个月,LOH低组5.2个月。
- BRCA突变组较LOH低组无进展生存期显著延长,风险比0.27(95%CI 0.16-0.44,p<0.0001)。
- LOH高组较LOH低组无进展生存期显著延长,风险比0.62(95%CI 0.42-0.90,p=0.011)。
核心结论
- 在BRCA突变或BRCA野生型且LOH高的铂敏感卵巢癌患者中,Rucaparib治疗后的无进展生存期长于BRCA野生型LOH低患者。
- 作者认为,肿瘤LOH评估可用于识别可能从Rucaparib获益的BRCA野生型铂敏感卵巢癌患者。
- 这些结果扩展了PARP抑制剂在BRCA突变肿瘤之外的潜在用途。
研究设计与样本
- ARIEL2是一项国际、多中心、两部分、2期、开放标签研究,在澳大利亚、加拿大、法国、西班牙、英国和美国的49家医院和癌症中心进行。
- 第1部分纳入复发性、铂敏感、高级别卵巢癌患者,依据肿瘤突变分析分为BRCA突变(有害胚系或体细胞)、BRCA野生型且LOH高、BRCA野生型且LOH低三个预设同源重组缺陷亚组。
- 预设基因组LOH≥14%为LOH高。
- 患者接受口服Rucaparib 600 mg每日两次,连续28天为一周期,直至疾病进展或任何其他原因停药。
- 256例患者接受筛选,206例于2013年10月30日至2014年12月19日入组;数据截止日期(2016年1月18日)时204例接受Rucaparib治疗,28例仍在研究中。
主要发现
- 192例患者可分类至三个预设同源重组缺陷亚组:BRCA突变组(n=40)、LOH高组(n=82)、LOH低组(n=70)。
- 12例患者肿瘤为BRCA野生型,但因样本中肿瘤细胞核不足无法进行LOH分类。
- 204例患者的中位治疗持续时间为5.7个月(IQR 2.8-10.1)。
- BRCA突变组24例、LOH高组56例、LOH低组59例患者出现疾病进展或死亡。
- Rucaparib治疗后中位无进展生存期:BRCA突变组12.8个月(95%CI 9.0-14.7),LOH高组5.7个月(95%CI 5.3-7.6),LOH低组5.2个月(95%CI 3.6-5.5)。
关键数值与推荐
- BRCA突变组较LOH低组无进展生存期显著延长,风险比0.27(95%CI 0.16-0.44,p<0.0001)。
- LOH高组较LOH低组无进展生存期显著延长,风险比0.62(95%CI 0.42-0.90,p=0.011)。
- 最常见的3级或以上治疗中出现的不良事件为贫血或血红蛋白降低(45例[22%]患者)和丙氨酸氨基转移酶或天冬氨酸氨基转移酶升高(25例[12%])。
- 常见严重不良事件包括小肠梗阻(204例中10例[5%])、恶性肿瘤进展(10例[5%])和贫血(9例[4%])。
- 研究期间3例患者死亡(2例因疾病进展,1例因脓毒症和疾病进展);无治疗相关死亡。
临床怎么用
- 作者认为,肿瘤LOH评估可用于识别可能从Rucaparib获益的BRCA野生型铂敏感卵巢癌患者。
- 作者认为,这些结果扩展了PARP抑制剂在BRCA突变肿瘤之外的潜在用途。
局限性
- 12例患者肿瘤为BRCA野生型,但因样本中肿瘤细胞核不足无法进行LOH分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homologous recombination deficiency. In ARIEL2, we assessed the ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor. METHODS: ARIEL2 is an international, multicentre, two-part, phase 2, open-label study done at 49 hospitals and cancer centres in Australia, Canada, France, Spain, the UK, and the USA. In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three predefined homologous recombination deficiency subgroups on the basis of tumour mutational analysis: BRCA mutant (deleterious germline or somatic), BRCA wild-type and LOH high (LOH high group), or BRCA wild-type and LOH low (LOH low group). We prespecified a cutoff of 14% or more genomic LOH for LOH high. Patients began treatment with oral rucaparib at 600 mg twice per day for continuous 28 day cycles until disease progression or any other reason for discontinuation. The primary endpoint was progression-free survival. All patients treated with at least one dose of rucaparib were included in the safety analyses and all treated patients who were classified were included in the primary endpoint analysis. This trial is registered with ClinicalTrials.gov, number NCT01891344. Enrolment into ARIEL2 Part 1 is complete, although an extension (Part 2) is ongoing. FINDINGS: 256 patients were screened and 206 were enrolled between Oct 30, 2013, and Dec 19, 2014. At the data cutoff date (Jan 18, 2016), 204 patients had received rucaparib, with 28 patients remaining in the study. 192 patients could be classified into one of the three predefined homologous recombination deficiency subgroups: BRCA mutant (n=40), LOH high (n=82), or LOH low (n=70). Tumours from 12 patients were established as BRCA wild-type, but could not be classified for LOH, because of insufficient neoplastic nuclei in the sample. The median duration of treatment for the 204 patients was 5·7 months (IQR 2·8-10·1). 24 patients in the BRCA mutant subgroup, 56 patients in the LOH high subgroup, and 59 patients in the LOH low subgroup had disease progression or died. Median progression-free survival after rucaparib treatment was 12·8 months (95% CI 9·0-14·7) in the BRCA mutant subgroup, 5·7 months (5·3-7·6) in the LOH high subgroup, and 5·2 months (3·6-5·5) in the LOH low subgroup. Progression-free survival was significantly longer in the BRCA mutant (hazard ratio 0·27, 95% CI 0·16-0·44, p<0·0001) and LOH high (0·62, 0·42-0·90, p=0·011) subgroups compared with the LOH low subgroup. The most common grade 3 or worse treatment-emergent adverse events were anaemia or decreased haemoglobin (45 [22%] patients), and elevations in alanine aminotransferase or aspartate aminotransferase (25 [12%]). Common serious adverse events included small intestinal obstruction (10 [5%] of 204 patients), malignant neoplasm progression (10 [5%]), and anaemia (nine [4%]). Three patients died during the study (two because of disease progression and one because of sepsis and disease progression). No treatment-related deaths occurred. INTERPRETATION: In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas. Our results suggest that assessment of tumour LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib. These results extend the potential usefulness of PARP inhibitors in the treatment setting beyond BRCA mutant tumours. FUNDING: Clovis Oncology, US Department of Defense Ovarian Cancer Research Program, Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant, and V Foundation Translational Award.
引用
- Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016. PMID: 27908594. doi:10.1016/S1470-2045(16)30559-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。